SERA
SERA PROGNOSTICS, INC.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$2.09
+0.72%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$2.07
From 52W high−44.40%
Volume92086.00
Market cap$82.25M
P/E (TTM)—
P/S (TTM)1175.0x
Div yield—
Key dataSep 18, 2026
Open
$2.07
From 52W high
−44.40%
Volume
92086.00
Market cap
$82.25M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.2x
P/E (TTM)
—
RSI (14)
55.0
MomentumView details →
1D Return
+0.72%
YTD Return
−29.15%
SummaryUpdated Jun 1, 2026
Sera Prognostics, Inc. (NASDAQ:SERA) is a women's health diagnostic company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in July 2021 and focuses on developing blood-based biomarker tests to predict and improve pregnancy outcomes. Sera Prognostics operates in the specialized field of prenatal diagnostics, addressing one of healthcare's most pressing challenges: preterm birth, which affects approximately 1 in 10 babies born in the United States and has seen rates increase by 12% between 2014-2022.
Similar companies
Latest newsMore news →